JP2008501034A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501034A5
JP2008501034A5 JP2007515456A JP2007515456A JP2008501034A5 JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5 JP 2007515456 A JP2007515456 A JP 2007515456A JP 2007515456 A JP2007515456 A JP 2007515456A JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5
Authority
JP
Japan
Prior art keywords
formulation
buffer system
posaconazole
agent
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007515456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501034A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018945 external-priority patent/WO2005117831A1/en
Publication of JP2008501034A publication Critical patent/JP2008501034A/ja
Publication of JP2008501034A5 publication Critical patent/JP2008501034A5/ja
Withdrawn legal-status Critical Current

Links

JP2007515456A 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液 Withdrawn JP2008501034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28
PCT/US2005/018945 WO2005117831A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Publications (2)

Publication Number Publication Date
JP2008501034A JP2008501034A (ja) 2008-01-17
JP2008501034A5 true JP2008501034A5 (US07981874-20110719-C00313.png) 2008-07-03

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515456A Withdrawn JP2008501034A (ja) 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液

Country Status (15)

Country Link
EP (1) EP1761247A1 (US07981874-20110719-C00313.png)
JP (1) JP2008501034A (US07981874-20110719-C00313.png)
KR (1) KR20070027564A (US07981874-20110719-C00313.png)
CN (1) CN1988887A (US07981874-20110719-C00313.png)
AR (1) AR049063A1 (US07981874-20110719-C00313.png)
AU (1) AU2005249502A1 (US07981874-20110719-C00313.png)
CA (1) CA2567803A1 (US07981874-20110719-C00313.png)
IL (1) IL179627A0 (US07981874-20110719-C00313.png)
MX (1) MXPA06013886A (US07981874-20110719-C00313.png)
NO (1) NO20066005L (US07981874-20110719-C00313.png)
PE (1) PE20060291A1 (US07981874-20110719-C00313.png)
RU (1) RU2006146555A (US07981874-20110719-C00313.png)
TW (1) TWI290051B (US07981874-20110719-C00313.png)
WO (1) WO2005117831A1 (US07981874-20110719-C00313.png)
ZA (1) ZA200609890B (US07981874-20110719-C00313.png)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
CA2651726C (en) 2006-05-12 2015-12-15 Pharmacon - Forschung Und Beratung Gmbh Use of combination preparations, comprising antimycotics
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
EP2451805A1 (en) 2009-07-09 2012-05-16 Sandoz AG A crystalline form of posaconazole
CN102906087B (zh) 2010-05-19 2016-03-23 桑多斯股份公司 制备手性三唑酮的方法
RU2585683C2 (ru) 2010-05-19 2016-06-10 Сандоз Аг Очистка позаконазола и промежуточных продуктов для синтеза позаконазола
RU2580318C2 (ru) 2010-05-19 2016-04-10 Сандоз Аг Получение промежуточных продуктов для синтеза позаконазола
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
ES2893444T3 (es) * 2010-06-29 2022-02-09 Merck Sharp & Dohme Formulaciones de posaconazol en solución intravenosa estabilizadas mediante beta-ciclodextrina sustituida
CA2838051C (en) 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound
CN103284959B (zh) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 泊沙康唑冻干粉针剂及制备方法
CN102755628B (zh) * 2012-07-16 2013-10-23 中国科学院微生物研究所 一种抗真菌的药物组合物
CN102805731B (zh) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 泊沙康唑干混悬剂及其制备方法
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
CA3056919A1 (en) * 2017-03-26 2018-10-04 Vivi Robyn Stafford Method of treatment of skin conditions of eye lids
CN111093373A (zh) * 2017-04-12 2020-05-01 V·J·班格万丁 组合物、包装的药物和使用泊沙康唑用于敏化抗性肿瘤的方法
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
CN111514146A (zh) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 含有泊沙康唑的药物组合物
CN113933131B (zh) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 一种阴道微生物荧光染色液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU2002257104B2 (en) * 2001-04-03 2006-02-09 Merck Sharp & Dohme Corp. Antifungal composition with enhanced bioavailability

Similar Documents

Publication Publication Date Title
JP2008501034A5 (US07981874-20110719-C00313.png)
JP5681693B2 (ja) 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
McShane et al. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug–device combination
EP3067046B1 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
US5648399A (en) Liquid polymer composition and method of use
Pastor et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis
US5160737A (en) Liquid polymer composition, and method of use
ES2875584T3 (es) Formulación para inhalación líquida que comprende RPL554
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
ES2525163T3 (es) Método para preparar composiciones farmacéuticas pretendidas para administración oral que comprenden uno o más ingredientes activos y las composiciones que comprenden los mismos
CA2467611A1 (en) Azithromycin dosage forms with reduced side effects
Zillen et al. Natural and bioinspired excipients for dry powder inhalation formulations
JP2015517522A (ja) 実質的に水不溶性の薬物の送達のための医薬組成物
CZ299348B6 (cs) Aerosolový prostredek
García et al. Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution
ES2928399T3 (es) Composición farmacéutica bactericida que comprende ibuprofeno
US20220287996A1 (en) Methods and compositions for treating edema refractory to oral diuretics
JP2007091686A (ja) ヒノキチオールを含有するナノ粒子
US20220151944A1 (en) Fluorouracil-containing formulations
US20210077449A1 (en) Formulations Having Anti-inflammatory Activity and Antimicrobial Activity Against Gram-Positive Bacteria
JPH0617300B2 (ja) 歯周疾患治療用組成物
ES2883144T3 (es) Efectos sinérgicos que incrementan los efectos antimicrobianos de los lípidos
US20220152092A1 (en) Microbial removal
TW202227104A (zh) 預防感染之組合物
JP2006518719A (ja) ヘルペスの治療のためのpvp−ヨウ素リポソームの使用